Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction

BMC Cardiovascular Disorders

Volumn 16, Issue 1, 2016, Pages

  Halvorsen, Sigrun ^a   Jortveit, Jarle ^b   Hasvold, Pål ^c   Thuresson, Marcus ^d   Øie, Erik ^e  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Sørlandet Hospital   (Norway)

^c ASTRAZENECA R AND D   (Sweden)

^d STATISTICON AB   (Sweden)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Acute myocardial infarction; Medication adherence; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; PRASUGREL; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; SOTALOL; TICAGRELOR; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION; AGED; COMBINATION DRUG THERAPY; MIDDLE AGED; MYOCARDIAL INFARCTION; NORWAY; PRACTICE GUIDELINE; PROCEDURES; PROTOCOL COMPLIANCE; REGISTER; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; NORWAY; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 85007481081     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-016-0283-6     Document Type: Article

References (21)

1. Patient statistics, 2014. Available at: https://www.ssb.no/en/helse/statistikker/pasient. Accessed 1 Oct 2015.
2. Jortveit J, Govatsmark RE, Digre TA, Risøe C, Hole T, Mannsverk J, Slørdahl SA, Halvorsen S. Myocardial infarction in Norway in 2013. Tidsskr Nor Legeforen. 2014;134:1841-6.
3. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-660.
4. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D. ESC Committee for Practice Guidelines ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology. Eur Heart J. 2011;32:2999-54.
5. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M. ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-45.
6. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-19.
7. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey Jr DE, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126:875-910.
8. Sørensen R, Gislason GH, Fosbøl EL, Rasmussen S, Køber L, Madsen JK, Torp-Pedersen C, Abildstrom SZ. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol. 2008;66:875-84.
9. Varenhorst C, Jensevik K, Jernberg T, Sundstrom A, Hasvold P, Held C, Lagerqvist B, James S. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J. 2014;35:969-78.
10. Hambraeus K, Tydén P, Lindahl B. Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDEHEART registry. Eur J Prev Cardiol. 2015. [Epub ahead of print]
11. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. EUROASPIRE Study Group EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121-37.
12. Gislason GH, Rasmussen JN, Abildstrøm SZ, Gadsbøll N, Buch P, Friberg J, Rasmussen S, Køber L, Stender S, Madsen M, Torp-Pedersen C. Longterm compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153-8.
13. Shore S, Jones PG, Maddox TM, Bradley SM, Stolker JM, Arnold SV, Parashar S, Peterson P, Bhatt DL, Spertus J, Ho PM. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction. Heart. 2015;101:800-7.
14. Bakken IJ, Nyland K, Halsteinli V, Kvam U, Skjeldestad F. Norsk pasientregister: administrativ database med mange forskningsmuligheter. Nor Epidemiol. 2004; 14:65-9.
15. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106:86-94.
16. The Cause of Death Register. https://www.ssb.no/en/helse/statistikker/pasient10. Accessed 1 Oct 2015.
17. Core Team R. R Foundation for Statistical Computing. Vienna: Austria. URL; 2015 R: A language and environment for statistical computing, https://www. r-project.org/.
18. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163-70.
19. Angerås O, Hasvold P, Thuresson M, Deleskog A, Braun O. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study. Scand Cardiovasc J. 2016;50:99-107.
20. Nytt om legemidler. http://tidsskriftet.no/Ekstra/Nytt-om-legemidler/Nytt-omlegemidler-2011 Accessed 1 Oct 2015.
21. Hassani S, Lindman AS, Kristoffersen DT, Tomic O, Helgeland J. 30-Day Survival Probabilities as a Quality Indicator for Norwegian Hospitals: Data Management and Analysis. PLoS One. 2015;10, e0136547.